CLDN18 and gastric cancer: To support treatment selection the Japan Gastric Cancer Association and the Pan-Asia European Society for Medical Oncology Clinical Practice Guidelines recommend simultaneous testing for four biomarkers: HER-2, CLDN18.2, PD-L1, and MSI/mismatch repair [18, 19].